Palvella Therapeutics (PVLA) Director M Sells $886K of Stock
Director Jenkins George M sold 7,174 shares on October 14, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jenkins George M, Director at Palvella Therapeutics, Inc. ($PVLA), sold 7,174 shares at an average price of $123.49, worth about $885,913.67, on October 14, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $PVLA is down 1.9% to date (from the $122.58 close on Oct 14, 2026).
PVLA
Palvella Therapeutics, Inc.
Key Points
- Jenkins George M sold 7,174 shares of Palvella Therapeutics at $123.49 each, for a total of about $885,914 on October 14, 2026.
- Palvella Therapeutics trades at $119.43, significantly below its 52-week high of $161.38.
- Analysts are bullish with a consensus rating of 'strong buy' and a mean price target of $230.53.
Get $PVLA trade alerts by text
We text you when insiders, Congress or big funds trade $PVLA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Palvella Therapeutics, Inc. alert may contain errors. Disclosures
Jenkins George M, a Director at Palvella Therapeutics, Inc. (NASDAQ: PVLA), sold 7,174 shares on October 14, 2026, for approximately $885,914. The shares were sold at an average price of $123.49. This transaction was noted as planned.
Jenkins George M vs. the S&P 500
Hypothetical returns from Jenkins George M's disclosed trades, not real profit or advice. How we model this.
Inside Jenkins George M's Trade
George Jenkins sold 7,174 shares of Palvella Therapeutics, reducing his holdings. This sale comes as the stock trades around $119.43, which is notably lower than its peak of $161.38 over the last year.
Other Institutional Activity in Palvella Therapeutics
Several institutional investors have made adjustments to their positions in Palvella. Montanova Capital LLC trimmed its stake by 18,110 shares, ending up with 1,135,406 shares valued at approximately $136.8 million. Meanwhile, Jennison Associates LLC added 319,993 shares, bringing its total to 960,619 shares worth about $115.8 million. Blackrock Inc. increased its position by 231,530 shares, now holding 918,357 shares valued at around $110.7 million. Frazier Life Sciences Management, L.P. maintained its holdings at 882,400 shares, while First Light Asset Management, LLC decreased its stake by 208,913 shares, resulting in 771,901 shares valued at about $93.0 million.
Palvella Therapeutics, Inc. Stock Down 6.2%
Palvella Therapeutics shares are currently trading at $119.43, well below the previous close of $150.56. The stock has experienced significant fluctuations, hitting a 52-week low of $56.55. It is important to note that the company's 50-day moving average stands at $149.36, indicating it is trading below this level.
Recent Earnings
In its most recent earnings report, Palvella Therapeutics reported a negative EPS of -$4.85. The next earnings report is scheduled for November 11, 2026. The company continues to focus on developing treatments for rare genetic skin diseases.
Analysts Set New Price Targets
On October 12, 2026, HC Wainwright & Co. maintained its 'Buy' rating for Palvella with a price target of $246.00, down from $270.00. Chardan Capital also maintains a 'Buy' rating with a price target of $240.00, unchanged from before. Recently, on October 16, William Blair initiated coverage with an 'Outperform' rating.
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, PA. The company specializes in developing therapies for serious and rare genetic skin diseases. Its lead candidate, QTORIN rapamycin, is in late-stage trials for treating complex lymphatic malformations.
Bottom Line
Investors should watch for the upcoming earnings report on November 11, 2026, which may provide further insights into the company's performance and strategy. The recent insider trades, especially Jenkins' activity, reflect ongoing adjustments in the company’s ownership landscape. Remember, the 13F filings represent past positions and may not reflect current holdings.
Related Filing Alerts
Source: Jenkins George M's Form 4 filing on $PVLA (Oct 14, 2026). Find the original filing: PVLA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts